Unknown

Dataset Information

0

Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.


ABSTRACT: The expression of estrogen receptor ? (ER) in breast cancers may be indicative of a favorable prognosis and most of these cancers respond to anti-estrogens or aromatase inhibitors. However, ER-positive (ER+) breast cancers receiving anti-hormone and/or chemotherapy sometimes lose their ER expression, which leads to the evolution of the disease to higher aggressiveness and drug resistance. In the present study, an ER-modified signature (EMS) was developed from the expression profile of a chemoresistant MCF-7 breast cancer cell line that lost ER expression during long-term treatment with a chemotherapeutic agent. The EMS could discriminate the ER-negative (ER-) breast cancer cells from the ER+ ones, which included seven pathways essential for the ER- cell development. Furthermore, the EMS indicated a more malignant subgroup of the ER- cells by discriminating the chemoresistant ER- cells from the chemosensitive ones. In addition, the classified chemoresistant ER- patients demonstrated worse prognosis. In conclusion, we developed a new method to discriminate subgroups of ER- breast cancer cells.

SUBMITTER: He DX 

PROVIDER: S-EPMC5783585 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.

He Dong-Xu DX   Wu Xiao-Li XL   Lu Chun-Xiao CX   Gu Xiao-Ting XT   Zhang Guang-Yuan GY   Ma Xin X   Liu De-Quan DQ  

Oncology reports 20171012 6


The expression of estrogen receptor α (ER) in breast cancers may be indicative of a favorable prognosis and most of these cancers respond to anti-estrogens or aromatase inhibitors. However, ER-positive (ER+) breast cancers receiving anti-hormone and/or chemotherapy sometimes lose their ER expression, which leads to the evolution of the disease to higher aggressiveness and drug resistance. In the present study, an ER-modified signature (EMS) was developed from the expression profile of a chemores  ...[more]

Similar Datasets

| S-EPMC3635895 | biostudies-literature
| S-EPMC6356506 | biostudies-literature
| S-EPMC3858893 | biostudies-other
2020-12-07 | GSE140406 | GEO
| S-EPMC5528595 | biostudies-literature
| S-EPMC7867078 | biostudies-literature
| S-EPMC9051105 | biostudies-literature
| S-EPMC2593438 | biostudies-literature
| S-EPMC3046434 | biostudies-literature
| S-EPMC3977241 | biostudies-literature